Keywords: promising, ph, iia, data, roche, r1626, swiss
Promising Ph IIa data on Roche's R1626
Article | 05 May 2008
Swiss drug major Roche's investigational therapy for chronic hepatitis C virus infection, R1626, showed a significant end-of-treatment response rate when ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
